Betaloc IV

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Metoprolol tartrate 1 mg/mL;  

Pieejams no:

AstraZeneca Limited

SNN (starptautisko nepatentēto nosaukumu):

Metoprolol tartrate 1 mg/mL

Deva:

1 mg/mL

Zāļu forma:

Solution for injection

Kompozīcija:

Active: Metoprolol tartrate 1 mg/mL   Excipient: Sodium chloride Water for injection

Vienības iepakojumā:

Ampoule, glass, 5 mL, 5 dose units

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Ipca Laboratories Limited

Ārstēšanas norādes:

Betaloc IV is indicated for the following indications: · Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · Suspected or definite myocardial infarction.

Produktu pārskats:

Package - Contents - Shelf Life: Ampoule, glass, 5 mL - 5 dose units - 60 months from date of manufacture stored at or below 25°C protect from light

Autorizācija datums:

1981-08-28

Produkta apraksts

 
Betaloc IV Data Sheet 050411 
Copyright 
1
NEW ZEALAND DATA SHEET 

NAME OF MEDICINE 

B
ETALOC 
IV 
metoprolol tartrate 1 mg/mL injection 

PRESENTATION 

Ampoule – a clear, colourless liquid free from foreign particles
containing 5 mL of 1 mg/mL 
metoprolol tartrate. 

USES 

ACTIONS 
Metoprolol is a beta
1
-selective beta-blocker, ie. it blocks beta
1
–receptors at doses much 
lower than those needed to block beta
2
-receptors. 

Metoprolol has an insignificant membrane-stabilising effect and does
not display partial 
agonist activity. 

Metoprolol reduces or inhibits the agonistic effect on the heart
of catecholamines (which are 
released during physical and mental stress).  This
means that the usual increase in heart 
rate, cardiac output, cardiac contractility
and blood pressure, produced by the acute increase 
in catecholamines, is reduced by metoprolol. 

During high endogenous adrenaline levels
metoprolol interferes much less with blood 
pressure control than non-selective beta-blockers. 

When mandatory, metoprolol , in combination with a beta
 2
-agonist, may be given to patients 
with symptoms of obstructive pulmonary disease.  When given
together with a beta
2
-agonist, 
metoprolol in therapeutic doses interferes less than non-selective
beta-blockers with the 
beta
2
-mediated bronchodilation  caused by the beta
2
-agonist. 

Metoprolol interferes less with insulin release and carbohydrate
metabolism than do non-
selective beta-blockers. 

Metoprolol interferes much less with the cardiovascular response
to hypoglycaemia than do 
non-selective beta-blockers.  

Short term studies have shown that metoprolol may cause a slight
increase in triglycerides 
and a decrease in free fatty acids in the blood.  In some cases, a
small decrease in the high 
density lipoproteins (HDL) fraction has been observed, although to a
lesser extent than that 
following non-selective beta-blockers.  Howe